Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Rebecca J Nagy"'
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-13 (2024)
Abstract Background We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more dura
Externí odkaz:
https://doaj.org/article/c30874be81f04b78be67858f937fdb82
Autor:
Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/4cc93b26e3c04e74a206892c9a22fe0a
Autor:
Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw, Rebecca J. Nagy
Publikováno v:
Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-6 (2019)
Abstract Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent m
Externí odkaz:
https://doaj.org/article/a2642d01b2c14be0a9b216a7597b136a
Autor:
Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Angel L. Guerrero-Zotano, Sarah Croessmann, Yan Guo, Paula Gonzalez Ericsson, Kyung-min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Rocha Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-est
Externí odkaz:
https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d4
Autor:
Brian M. Wolpin, Scott L. Carter, Ryan B. Corcoran, William C. Hahn, Jen Jen Yeh, Nikhil Wagle, David A. Tuveson, Paul B. Shyn, Jeffrey W. Miller, Robert J. Mayer, Matthew H. Kulke, Bruce E. Johnson, Jason L. Hornick, Gad Getz, Levi A. Garraway, Charles S. Fuchs, Matthew B. Yurgelun, Dean J. Welsch, Deborah Knoerzer, Richard B. Lanman, Rebecca J. Nagy, Stuart G. Silverman, Ewa Sicinska, Geoffrey I. Shapiro, Marvin Ryou, Douglas A. Rubinson, Michael H. Rosenthal, Kimberly Perez, Anuj K. Patel, Kimmie Ng, Janet E. Murphy, Jeffrey A. Meyerhardt, Nadine J. McCleary, Kunal Jajoo, Leona A. Doyle, James M. Cleary, Thomas Clancy, Kelly P. Burke, Joseph P. St. Pierre, Heather A. Shahzade, Emily E. Van Seventer, Brandon Nadres, Annacarolina Da Silva, Ana Babic, Nelly Oliver, Karla Helvie, Kristin Anderka, Lori Marini, Devin McCabe, Emma Reilly, Marisa W. Welch, Dorisanne Ragon, Lauren K. Brais, Jaegil Kim, Srivatsan Raghavan, Mehlika Hazar-Rethinam, Arezou A. Ghazani, Richard A. Moffitt, Nicholas D. Camarda, Jonathan A. Nowak, Andrew J. Aguirre
MAF file for copy number variations identified in the cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a50ef08101f64b6034b9a8359c272e7a
https://doi.org/10.1158/2159-8290.22532632
https://doi.org/10.1158/2159-8290.22532632
Autor:
Daniel V. Catenacci, Adam J. Bass, Jeeyun Lee, Viktor Adalsteinsson, Yu Imamura, Jon Davison, Denisse Rotem, Greg Gydush, Sarah Reed, Justin Rhoades, Samuel S. Freeman, Gavin Ha, Andres Gelrud, Uzma Siddiqui, Kyle Hogarth, Paul Chang, Kiran Turaga, Kevin Roggin, Mitchell C. Posner, Yuan Ji, Haley A. Coleman, Bruce M. Wollison, Matthew D. Ducar, Aaron R. Thorner, Andrew Dunford, David J. Oh, Agoston T. Agoston, Rick Lanman, Hideo Baba, Masayuki Watanabe, Lea O'Keefe, Katie S. Nason, Byung-Hoon Min, Min-Gew Choi, Kyoung-Mee Kim, Rebecca J. Nagy, John Hart, Shu-Yuan Xiao, Namrata Setia, Christopher Weber, Carrie Fitzpatrick, Rajani Kanteti, Melissa Maranto, Samantha Lomnicki, Emily O'Day, Kenisha Allen, Manish R. Sharma, Blase Polite, Hedy Kindler, Heewon Kwak, Lindsay Alpert, Mirazul Islam, Steven Maron, Yang Liu, Sarah Derks, Matthew D. Stachler, Eirini Pectasides
Supplementary Fig. 1: Mutation rate and ploidy for each individual patient's primary and metastatic sample (cohort 1);Supplementary Fig. 2: Validation of genomic heterogeneity within primary tumor and between primary tumor and lymph node (LN) metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::983d30a92fc5950bf814c139a986a833
https://doi.org/10.1158/2159-8290.22534244.v1
https://doi.org/10.1158/2159-8290.22534244.v1
Autor:
Yelena Y. Janjigian, Nikolaus Schultz, Maurizio Scaltriti, Jorge A. Carrasquillo, David B. Solit, Jason S. Lewis, Barry S. Taylor, Elisa de Stanchina, Michael F. Berger, Wolfgang A. Weber, David H. Ilson, Christine A. Iacobuzio-Donahue, Heiko Schöder, Neeta Pandit-Taskar, Steven M. Larson, Richard B. Lanman, Rebecca J. Nagy, Todd Hembrough, Yuan Tian, Fabiola Cecchi, Besnik Qeriqi, Marissa Mattar, Marinela Capanu, Mario E. Lacouture, Karen Brown, Robert A. Lefkowitz, David P. Kelsen, Mark Schattner, Efsevia Vakiani, Joanne Soong, Gouri J. Nanjangud, Nancy Bouvier, Christopher J. Fong, Helen Won, Yaelle Tuvy, Geoffrey Y. Ku, Pau Castel, Jaclyn F. Hechtman, Francisco Sanchez-Vega
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d345f251f584820ded04c6ed942e8f7
https://doi.org/10.1158/2159-8290.22532891
https://doi.org/10.1158/2159-8290.22532891
Autor:
Daniel V. Catenacci, Adam J. Bass, Jeeyun Lee, Viktor Adalsteinsson, Yu Imamura, Jon Davison, Denisse Rotem, Greg Gydush, Sarah Reed, Justin Rhoades, Samuel S. Freeman, Gavin Ha, Andres Gelrud, Uzma Siddiqui, Kyle Hogarth, Paul Chang, Kiran Turaga, Kevin Roggin, Mitchell C. Posner, Yuan Ji, Haley A. Coleman, Bruce M. Wollison, Matthew D. Ducar, Aaron R. Thorner, Andrew Dunford, David J. Oh, Agoston T. Agoston, Rick Lanman, Hideo Baba, Masayuki Watanabe, Lea O'Keefe, Katie S. Nason, Byung-Hoon Min, Min-Gew Choi, Kyoung-Mee Kim, Rebecca J. Nagy, John Hart, Shu-Yuan Xiao, Namrata Setia, Christopher Weber, Carrie Fitzpatrick, Rajani Kanteti, Melissa Maranto, Samantha Lomnicki, Emily O'Day, Kenisha Allen, Manish R. Sharma, Blase Polite, Hedy Kindler, Heewon Kwak, Lindsay Alpert, Mirazul Islam, Steven Maron, Yang Liu, Sarah Derks, Matthew D. Stachler, Eirini Pectasides
Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies is that genomic profiling results could common
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b6ea79102b00169cfaf145b8d3b0505
https://doi.org/10.1158/2159-8290.c.6547418.v1
https://doi.org/10.1158/2159-8290.c.6547418.v1
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
Overall sequencing CONSORT diagram. Flow diagram of study patients and analyzed biospecimens processed through and selected for central sequencing using MSK-IMPACT and Guardant360. cfDNA, cell-free DNA; FFPE, formalin-fixed paraffin-embedded; MSK-IMP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fadd31b50eb28b778540b40ef3547376
https://doi.org/10.1158/2159-8290.22535392.v1
https://doi.org/10.1158/2159-8290.22535392.v1
Autor:
Daniel V.T. Catenacci, Namrata Setia, Shu-Yuan Xiao, John Hart, Alexa Schrock, Todd Hembrough, Fabiola Cecchi, Richard B. Lanman, Rebecca J. Nagy, Emily O'Day, David Xu, Leah Chase, Samantha Lomnicki, Heewon A. Kwak, Lindsay Alpert, Steven B. Maron
Detailed patient information who were treated with anti-EGFR therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39916db9a0e606066a52d4ba26374b1d
https://doi.org/10.1158/2159-8290.22532506.v1
https://doi.org/10.1158/2159-8290.22532506.v1